Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase ii study of the german testicular cancer study group

SIR, We read with interest the phase II results presented by Kollmannsberger et al (2002b), which recorded no responses to single-agent irinotecan delivered in a dose of 300–350 mg/m−2 every

3 weeks. This led the authors to conclude that further evaluation of irinotecan in patients with germ cell cancer could not be recommended. We note that other recent single-agent phase II

studies in germ cell tumours (oxaliplatin, paclitaxel and gemcitabine (Sandler et al, 1998; Bokemeyer et al, 1999; Kollmannsberger et al, 2002a)) revealed very low objective response rates

(Table 1) The patients treated in the studies are invariably heterogenous; however, most have proved refractory to at least two lines of cisplatin-based therapy and many have received prior

high-dose therapy. Since the number of durable responses following high-dose therapy is of the region of only 4% and that 86% of patients in Kollmannsberger's manuscript had received

high-dose therapy, we feel that the results are not particularly surprising. The median survival in all these studies is remarkably similar and in the region of 3–6 months. However, when

gemcitabine and paclitaxel were given in combination, the overall survival was improved (Hinton et al, 2002). We have recently reported in this journal that there is an increased level of

topoisomerase-1 expression in viable tumour samples from residual masses postchemotherapy (Berney et al, 2002). Moreover, _in vitro_ studies suggest that the active metabolite of irinotecan

(SN38) may be active in germ cell tumours. Evidence for this comes from both published data (Ueno et al, 2002) and currently unpublished work in progress, from our institution. SN38 appears

to have impressive efficacy in both sensitive and platinum-resistant testicular cancer cell lines (sensitive testicular lines: IC50=1.8–7.4 nm, resistant testicular line: IC50=7.0 nm). It is

for this reason that we have felt that the investigation of combination chemotherapy based on irinotecan was warranted. We have been evaluating a combination chemotherapy regimen using

oxaliplatin 100 mg/ m−2 on 1 one, irinotecan 200 mg/ m−2 on day 1 and paclitaxel 80 mg/ m−2 on days 1, 8 and 15 (IPO), the treatment being repeated every 21 days. To date we have treated

nine patients. Two had absolutely refractory disease to cisplatin and two had relapsed following high-dose chemotherapy. Four patients have had complete remissions and two have marker

negative partial remissions. Currently, the median survival for this cohort has not been reached, with a median follow-up of 11 months (range 4–14). Both patients with absolute refractory

disease are currently progression free 11 and 12 months after treatment. We conclude that combining drugs with relatively low single-agent activity, leads to improved results in these

patients. This effect has also been shown when oxaliplatin and irinotecan were combined in fluorouracil-resistant colorectal carcinoma, as compared to their single-agent activity

(Scheithauer et al, 1999). Our results are certainly comparable with those of Nomoto _et al_, who also used irinotecan in combination with cisplatin in relapsed disease; however, details

regarding platinum sensitivity of their patients were not given (Nomoto _et al_, 2002). These _in vitro_ and _in vivo_ observations lead us to question whether single-agent phase II studies,

conducted in a highly refractory patient population may best be able to identify potentially useful cytotoxics, and certainly a negative result must be accepted with some degree of caution.

CHANGE HISTORY * _ 16 NOVEMBER 2011 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication _ REFERENCES * Berney

DM, Shamash J, Gaffney J, Jordan S, Oliver RT (2002) DNA topoisomerase I and II expression in drug resistant germ cell tumours. _Br J Cancer_ 87 (6): 624–629 Article  CAS  Google Scholar  *

Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. _J

Clin Oncol_ 17 (2): 512–516 Article  CAS  Google Scholar  * Hinton S, Catalano P, Einhorn LH, Loehrer Sr PJ, Kuzel T, Vaughn D, Wilding G (2002) Phase II study of paclitaxel plus gemcitabine

in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. _J Clin Oncol_ 20 (7): 1859–1863 Article  CAS  Google Scholar  * Kollmannsberger C, Rick O, Derigs

HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002a) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory

germ cell cancer: a study of the German Testicular Cancer Study Group. _J Clin Oncol_ 20 (8): 2031–2037 Article  CAS  Google Scholar  * Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer

HG, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002b) Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the

German Testicular Cancer Study Group. _Br J Cancer_ 87 (7): 729–732 Article  CAS  Google Scholar  * Miki T, Mizutani Y, Nonomura N, Nomoto T, Nakao M, Saiki S, Kotake T, Okuyama A (2002)

Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. _Cancer_ 95 (9): 1879–1885 Article  CAS  Google Scholar  * Sandler AB, Cristou A,

Fox S, Williams SD, Nichols CR, Turns M, Roth BJ (1998) A phase II trial of paclitaxel in refractory germ cell tumors. _Cancer_ 82 (7): 1381–1386 Article  CAS  Google Scholar  * Scheithauer

W, Kornek GV, Raderer M, Valencak J, Weinlander G, Hejna M, Haider K, Kwasny W, Depisch D (1999) Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients

with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. _J Clin Oncol_ 17 (3): 902–906 Article  CAS  Google Scholar  * Ueno M, Nonaka S, Yamazaki R, Deguchi N, Maurai M

(2002) SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. _Eur Urol_ 42: 390–397 Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Department of Medical Oncology, St Bartholomew's Hospital, 1st Floor, King George V Building, West Smithfield, ECIA 7BE, London, UK T Powles, J Shamash, D Berney & R

T D Oliver Authors * T Powles View author publications You can also search for this author inPubMed Google Scholar * J Shamash View author publications You can also search for this author

inPubMed Google Scholar * D Berney View author publications You can also search for this author inPubMed Google Scholar * R T D Oliver View author publications You can also search for this

author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to T Powles. RIGHTS AND PERMISSIONS From twelve months after its original publication, this work is licensed under the

Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Powles, T., Shamash, J., Berney, D. _et al._ Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the

German Testicular Cancer Study Group. _Br J Cancer_ 89, 1140–1141 (2003). https://doi.org/10.1038/sj.bjc.6601176 Download citation * Published: 09 September 2003 * Issue Date: 15 September

2003 * DOI: https://doi.org/10.1038/sj.bjc.6601176 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link

is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative